Saredutant
Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist.[1] It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.111.408 |
Chemical and physical data | |
Formula | C31H35Cl2N3O2 |
Molar mass | 552.54 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
See also
References
- Hopkins CR (October 2010). "ACS chemical neuroscience molecule spotlight on Saredutant". ACS Chemical Neuroscience. 1 (10): 653–4. doi:10.1021/cn100061r. PMC 3368631. PMID 22776916.
- "Letter to the stockholders of Sanofi-Aventis" (PDF). May 2009. Archived from the original (PDF) on 21 December 2010.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.